GlobeNewswire·Nov 13, 2026, 8:02 AM ET

Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth

BFRI BFRIW

Biofrontera Inc. reported net product revenue of $9.1 million for the third quarter ended September 30, 2026, representing a 29.8% increase from $7.0 million in the prior-year period.
Gross margin improved to 74.4% in the third quarter from 70.7% in the prior year, driven by a lower cost structure from the October 2025 strategic transaction with Biofrontera AG.
The company recorded a net loss of $6.4 million, or $0.42 per share, for the third quarter, compared to a net loss of $6.6 million, or $0.62 per share, in the prior-year period.
Adjusted EBITDA for the third quarter was $(5.5) million, an improvement from $(6.0) million in the prior-year period.
On September 9, 2026, the FDA approved Ameluz plus Red-Light as the first photodynamic therapy approved in the U.S. for treating superficial basal cell carcinoma (sBCC).
U.S. Customs and Border Protection ruled on September 14, 2026, that the redesigned RhodoLED XL-C lamp does not violate the ITC exclusion order, allowing its importation for the U.S. market.
For the nine months ended September 30, 2026, net product revenue reached $31.2 million, a 26.6% increase from $24.6 million in the prior-year period.
Gross margin for the nine-month period was 78.0%, up from 67.7% in the prior-year period.
Net loss for the nine months ended September 30, 2026, was $11.8 million, or $0.89 per share, compared to $16.2 million, or $1.67 per share, in the prior-year period.
Adjusted EBITDA for the nine-month period was $(9.3) million, compared to $(15.5) million in the prior-year period.
Cash and cash equivalents were $3.2 million as of September 30, 2026, down from $6.4 million as of December 31, 2025.
Total liabilities stood at $21.7 million as of September 30, 2026, including $4.7 million in convertible notes payable maturing in November 2027.
Biofrontera plans to begin commercializing Ameluz for sBCC in the fourth quarter of 2026 or first quarter of 2027.
The company submitted a supplemental New Drug Application in October to expand the Ameluz label for actinic keratosis to the extremities, neck, and trunk.
Selling, general, and administrative expenses increased to $12.5 million in the third quarter, driven by legal fees related to the ITC Matter, manufacturing costs, and sales commissions.
Research and development expenses decreased to $0.5 million in the third quarter, reflecting the substantial completion of clinical trials.
Patent remediation expenses related to the ITC Matter totaled $0.3 million in the third quarter and $0.7 million for the nine-month period.

Company: Biofrontera Inc.
Keywords: Nasdaq:BFRI , Biofrontera Inc., Biofrontera Inc., NASDAQ: BFRI, Third Quarter 2026, Financial Results, biopharmaceutical company, photodynamic therapy, dermatology